A new method for detecting intestinal dysbiosis by fecal steroidomics analysis

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K11603
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Tokyo Medical University
• Principal Investigator: Hirayama Takeshi 東京医科大学, 医学部, 准教授 (30449219)
• Co-Investigator(Kenkyū-buntansha): 本多 彰 東京医科大学, 医学部, 教授 (10468639) ; 宮崎 照雄 東京医科大学, 医学部, 准教授 (60532687)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 糞便 / コレステロール / ステロイド / 腸内細菌叢 / ディスバイオーシス / LC-MS/MS

Outline of Final Research Achievements

The aim of this study was to develop a simpler method for diagnosing clinical dysbiosis without genetic analysis of the intestinal microbiota. Steroids were extracted from feces, and the carbonyl and hydroxyl groups were derivatized with Girard's P hydrazine and picolinic acid. These steroids were analyzed simultaneously by HPLC-MS/MS (positive ESI-SRM) along with deuterium-labeled internal standards. We determined steroid fractions and intestinal microbiota using feces from mice with dysbiosis due to altered bile acid composition and high-fat/high-sucrose diet. The results showed that 5β-cholestan-3-one and coprostanol were decreased in dysbiosis, suggesting they could be used as biomarkers for dysbiosis.

Free Research Field

消化器内科学

Academic Significance and Societal Importance of the Research Achievements

近年、肥満や疾病の原因として腸内細菌叢の乱れ(dysbiosis)が非常に注目されているが、その診断には時間と費用のかかる腸内細菌のメタゲノム解析が必要であると考えられている。しかし、そこまでの詳細な解析は必要なく、臨床的にdysbiosisがあるかないか、もしあれば治療によって改善したか否かを簡易な方法で診断する手法を提案した点において、学術的にも社会的にも意義のある研究と考えられる。